Role of miRNA in the Development and Progression of Osteoarthritis and Osteoporosis- A Review Article

Rajeshwar Nath Srivastava¹, Rashmi Yadav¹, Shatakshi Pant¹, Saloni Raj², Sudeepti Ratan Srivastava¹, Amar Chand Sharma¹, Dharmendra Kumar

¹Department of Orthopaedic Surgery, King George’s Medical University, Nabiullah Road, Daliganj, Lucknow, U.P, India
²Westminster College, Utah, United States

*Corresponding Author: Rajeshwar Nath Srivastava, Department of Orthopaedic Surgery, King George’s Medical University, Nabiullah Road, Daliganj, Lucknow, U.P, India.

Received: December 19, 2022; Published: February 02, 2023

Abstract

Osteoporosis [OP] and Osteoarthritis [OA] have many things in common despite distinct pathophysiologies. Both Osteoporosis and Osteoarthritis are the most common musculoskeletal disorders, in the elderly, commonly affecting females. The incidence of both is increasing with a very high prevalence in an aging population. Both the diseases are multifactorial and remain largely understudied at the molecular level. Genetic and environmental factors have been recognized to have a major role in both. Several candidate genes have been found to have an association with both diseases and interestingly some of these are common having a role in both although they have not been studied in those suffering from both osteoporosis and osteoarthritis. Recent interest has been sought on the role of small ribonucleic acid such as microRNAs (miRNA) on various metabolic and genetic diseases. Numerous studies showed that these miRNAs are small non-coding sequences, nearly around 20-22 nucleotide base pairs that control the expressions of several genes whose altered expressions may lead to the bone formation imbalance and destruction. Background

Purpose of Review: Osteoporosis and Osteoarthritis are a form of bone disease that most commonly affects the middle-aged and elderly. Besides many treatments and advancements in medical sciences, these diseases are still difficult to treat. Hence, there is a need to find some more specified and advanced treatment modalities to prevent the progression as well as treatment of both diseases. In our review, the role of miRNA is being discussed in both diseases which may provide more evidence to understand the diseases such as OP and OA.

Findings: The articles were searched and included from PubMed, MEDLINE, and DOAJ Databases in the English language. We implemented the research terminologies ["Osteoporosis" "Osteoarthritis"] and ["miRNA in OS and OP”] and identified publications that directly discussed survival factors in subjects with both diseases. Since OS and OP can present itself in various ways, comprising radiography and biochemical profile to diagnose the disease and opt the appropriate treatment, comparison of comprehensive radiographic and microscopic findings is important.

Inclusion criteria: Only those articles focused on the role of miRNA in OP and OA.

Exclusion criteria: • Repetitive published literature. • No relevant information was given in the literature. • The articles without a control group.

Keywords: Osteoarthritis; Osteoporosis; miRNAs; Prognostic Marker

References

1. E Seeman and PD Delmas. “Bone quality-the material and structural basis of bone strength and fragility”. The New England Journal of Medicine 21 (2006): 2250-2261.
2. National Osteoporosis Foundation (NOF). America’s bone health: The state of osteoporosis and low bone mass in our nation (2002).
3. Sanghi D., et al. “The association of anthropometric measures and osteoarthritis knee in non-obese subjects: a cross sectional study”. Clinics 2 (2011): 275-279.
4. Awasthi V., et al. “A Randomized Controlled Trial: Evaluation of Yoga with Il6 as Biomarker in the Management of Knee Osteoarthritis”. International Journal of Health Sciences and Research (2010).
5. McCarthy JJ., et al. “Developmental dysplasia of the hip (DDH)”. Current Orthopaedics3 (2005): 223-230.
6. Bartel DP. “MicroRNAs: genomics, biogenesis, mechanism, and function”. Cell116 (2004): 281-297.
7. Li Y and Kowdley KV. “MicroRNAs in common human diseases”. Genomics, Proteomics and Bioinformatics5 (2012): 246-53.
8. L Gennari., et al. “MicroRNAs in bone diseases”. Osteoporosis International4 (2017): 1191-1213.
9. Y Li and KV Kowdley. “MicroRNAs in common human diseases”. Genomics, Proteomics and Bioinformatics5 (2012): 246-253.
10. C Seeliger., et al. “Five freely circulating miRNAs and bone tissue miRNAs are associated with osteoporotic fractures”. Journal of Bone and Mineral Research8 (2014): 1718-1728.
11. H Li., et al. “MicroRNA-21 promotes osteogenic differentiation by targeting small mothers against decapentaplegic 7”. Molecular Medicine Reports1 (2015): 1561-1567.
12. W Ma., et al. “Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma”. Tumour Biology12 (2014): 12467-12472.
13. J Meng., et al. “Identification of miR-194-5p as a potential biomarker for postmenopausal osteoporosis”. Peer-Reviewed Journal 3 (2015): e971.
14. Abdullah Y Mandourah1,8, Lakshminarayan Ranganath2, Roger Barraclough3, Sobhan Vinjamuri4, Robert Van’T Hof1, Sandra Hamill4, Gabriela Czanner5, Ayed A. Dera1,7, Duolao Wang6 and Dong L. Barraclough1
15. Mitchell PS., et al. “Circulating microRNAs as stable blood-based markers for cancer detection”. Proceedings of the National Academy of Sciences of the United States of America 105 (2008): 10513-10518.
16. Bernard NJ. “Osteoarthritis: circulating miRNAs-early osteoarthritis biomarkers?” Nature reviews Rheumatology 10 (2014): 197.
17. Kanellopoulou C., et al. “Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing”. Genes Development 19 (2005): 489-501.
18. Iliopoulos D., et al. “Integrative microRNA and proteomic approaches identify novel osteoarthritis genes and their collaborative metabolic and inflammatory networks”. PLoS One 3 (2008): e3740.
19. Jones SW., et al. “The identification of differentially expressed microRNA in osteoarthritic tissue that modulate the production of TNF-α and MMP13”. Osteoarthritis Cartilage 17 (2009): 464 - 472.
20. Tuddenham L., et al. “The cartilage specific microRNA-140 targets histone deacetylase 4 in mouse cells”. FEBS Letter 580 (2006): 4214-4217.
21. Miyaki S., et al. “MicroRNA-140 plays dual roles in both cartilage development and homeostasis”. Genes Development 24 (2010): 1173-1185.
22. Miyaki S., et al. “MicroRNA140 is expressed in differentiated human articular chondrocytes and modulates interleukin-1 responses”. Arthritis and Rheumatology 60 (2009): 2723-2730.
23. Tardif G., et al. “Regulation of the IGFBP-5 and MMP-13 genes by the microRNAs miR-140 and miR-27a in human osteoarthritic chondrocytes”. BMC Musculoskeletal Disorders 10 (2009): 148.
24. Skrzypa M., et al. “miRNA-146a-5p is upregulated in serum and cartilage samples of patients with osteoarthritis”. Polish Journal of Surgery 91 (2019): 1-5.
25. Zhang Y., et al. “MicroRNA-21 controls the development of osteoarthritis by targeting GDF-5 in chondrocytes”. Experimental and Molecular Medicine 2 (2014): e79.
26. Kong R., et al. “Combination of circulating miR-19b-3p, miR-122-5p and miR-486-5p expressions correlates with risk and disease severity of knee osteoarthritis”. American Journal of Translational Research6 (2017): 2852.
27. Mandourah AY., et al. “Circulating microRNAs as potential diagnostic biomarkers for osteoporosis”. Scientific Reports1 (2018): 1-10.
28. Song W., et al. “The emerging roles of long noncoding RNAs in bone homeostasis and their potential application in bone-related diseases”. DNA and Cell Biology6 (2020): 926-937.
29. Quan H., et al. “LncRNA-AK131850 sponges MiR-93-5p in newborn and mature osteoclasts to enhance the secretion of vascular endothelial growth factor a promoting vasculogenesis of endothelial progenitor cells”. Cellular Physiology and Biochemistry 1 (2018): 401-417.
30. Y Xu., et al. “MicroRNA-93 inhibits inflammatory cytokine production in LPS-stimulated murine macrophages by targeting IRAK4”. FEBS Letter 9 (2014): 1692-1698.
31. C Zhang., et al. “MiR-34a/miR-93 target c-ski to modulate the proliferaton of rat cardiac fibroblasts and extracellular matrix deposition in vivo and in vitro, Cell”. Signal 46 (2018): 145-153.
32. W Jing and W Jiang. “MicroRNA-93 regulates collagen loss by targeting MMP3 in human nucleus pulposus cells”. Cell Proliferation 3 (2015): 284-292.
33. M Kapoor., et al. “Role of proinflammatory cytokines in the pathophysiology of osteoarthritis”. Nature Reviews Rheumatology 1 (2011): 33-42.
34. Song J., et al. “A long non‐coding RNA, GAS5, plays a critical role in the regulation of miR‐21 during osteoarthritis”. Journal of Orthopaedic Research12 (2014): 1628-1635.
35. Xiong B., et al. “MiR-21 regulates biological behavior through the PTEN/PI-3 K/Akt signaling pathway in human colorectal cancer cells”. International Journal of Oncology 42 (2013): 219-228.
36. Panach L., et al. “Serum Circulating MicroRNAs as Biomarkers of Osteoporotic Fracture”. Calcified Tissue International 97 (2015): 495-505.
37. Seeliger C., et al. “Five freely circulating miRNAs and bone tissue miRNAs are associated with osteoporotic fractures”. Journal of Bone and Mineral Research8 (2014): 1718-1728.
38. Tuddenham L., et al. “The cartilage specific microRNA-140 targets histone deacetylase 4 in mouse cells”. FEBS Letter580 (2006): 4214-4217.
39. Song B., et al. “Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells”. Oncogene28 (2009): 4065-4074.
40. Malzkorn B., et al. “Identification and functional characterization of microRNAs involved in the malignant progression of gliomas”. Brain Pathology20 (2009): 539-550.
41. Miyaki S., et al. “MicroRNA-140 is expressed in differentiated human articular chondrocytes and modulates interleukin-1 responses”. Arthritis and Rheumatology 60 (2009): 2723-2730.
42. Akhtar N., et al. “MicroRNA-27b regulates the expression of MMP-13 in human osteoarthritis chondrocytes”. Arthritis and Rheumatology 62 (2010): 1361-1371.
43. Miyaki S., et al. “MicroRNA-140 plays dual roles in both cartilage development and homeostasis”. Genes Development (this issue) (2010).
44. Nakamura Y., et al. “Sox9 is upstream of microRNA-140 in cartilage”. Applied Biochemistry and Biotechnology 166 (2012): 64-71.
45. Wa Q., et al. “miRNA-140 inhibits C3H10T1/2 mesenchymal stem cell proliferation by targeting CXCL12 during transforming growth factor-β3-induced chondrogenic differentiation”. Molecular Medicine Reports2 (2017): 1389-1394.
46. Nakamura Y., et al. “Chondrocytespecific microRNA-140 regulates endochondral bone development and targets Dnpep to modulate bone morphogenetic protein signaling”. Molecular and Cellular Biology 31 (2011): 3019-3028.
47. Yang J., et al. “MiR-140 is co-expressed with Wwp2-C transcript and activated by Sox9 to target Sp1 in maintaining the chondrocyte proliferation”. FEBS Letter 585 (2011): 2992-2997.
48. Barter MJ., et al. “Genome-Wide MicroRNA and Gene Analysis of Mesenchymal Stem Cell Chondrogenesis Identifies an Essential Role and Multiple Targets for miR-140-5p”. Stem Cells 33 (2015): 3266-3280.
49. Karlsen TA., et al. “microRNA140 targets RALA and regulates chondrogenic differentiation of human mesenchymal stem cells by translational enhancement of SOX9 and ACAN”. Stem Cells and Development 23 (2014): 290-304.
50. Tardif G., et al. “Regulation of the IGFBP-5 and MMP-13 genes by the microRNAs miR-140 and miR27a in human osteoarthritic chondrocytes”. BMC Musculoskeletal Disorders 10 (2009): 148.
51. Pais H., et al. “Analyzing mRNA expression identifies Smad3 as a microRNA-140 target regulated only at protein level”. RNA 16 (2010): 489-494.

Citation

Citation: Rajeshwar Nath Srivastava., et al. “Role of miRNA in the Development and Progression of Osteoarthritis and Osteoporosis- A Review Article”.Acta Scientific Orthopaedics 6.3 (2023): 11-20.

Copyright

Copyright: © 2023 Rajeshwar Nath Srivastava., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.